Defining a new era of oligonucleotides

Defining a new era of oligonucleotides

News Release

Wave Life Sciences to Participate in Leerink Partners 7th Annual Global Healthcare Conference

February 8, 2018 at 7:30 AM EST

CAMBRIDGE, Mass., Feb. 08, 2018 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (NASDAQ:WVE), a biotechnology company focused on delivering transformational therapies for patients with serious, genetically-defined diseases, today announced that Paul Bolno, MD, MBA, President and Chief Executive Officer, will participate in a fireside chat at Leerink Partners 7th Annual Global Healthcare Conference at 10:00 a.m. ET on Wednesday, February 14, 2018 in New York, New York.

About Wave Life Sciences

Wave Life Sciences is a biotechnology company focused on delivering transformational therapies for patients with serious, genetically-defined diseases. Our chemistry platform enables the creation of highly specific, well characterized oligonucleotides designed to deliver superior efficacy and safety across multiple therapeutic modalities. Our pipeline is initially focused on neurological disorders and extends across several other therapeutic areas. For more information, please visit www.wavelifesci.com.

Investor Contact:

Jillian Connell
617-949-2981
jconnell@wavelifesci.com 

Media Contact:

Jose Juves
617-949-4708
jjuves@wavelifesci.com

Primary Logo

Source: Wave Life Sciences